After 3 months of semaglutide, the percentage of patients with EE decreased from 72.5 to 11.5%, the percentage of patients with external eating decreased from 27.5 to 10.1%, the percentage of patients with craving decreased from 49.3 to 21.7%, and the percentage of patients with savory craving decreased from 53.6 to 14.5% [59]
These beneficial effects were underpinned by a comprehensive modulation of the transcriptome and proteome, revealing that semaglutide reduced systemic inflammation and mitigated fibrosis and lipid accumulation through direct effects on key cellular and molecular pathways, including enhanced branched-chain amino acid catabolism
However, the specific side effects experienced can vary from person to person
Currently, a large number of ongoing clinical trials are being conducted worldwide to evaluate novel therapeutic strategies for MASLD, opening opportunities for the development of new drug candidates or combination therapies with synergistic effects or targeting distinct stages of disease progression
However, you cant have both
